

<b>Form PTO-1449 Modified</b>  List of Patent and Publications Cited by Applicant (Use several sheets if necessary)  U.S. Department of Commerce Patent and Trademark Office	Docket No. WYNC-0326 (AM101202NP)	Application No. 10/659,193
	Applicant Deborah Ann Evrard, et al.	
	Filing Date September 10, 2003	Group <del>1624</del> 1626
	Confirmation No. 5593	

## U. S. PATENT DOCUMENTS

Examiner Initial		Document No.	Date	Name	Class	Subclass
PS	20	5,468,767	11/21/95	Cipollina et al.	514	414
PS	21	5,607,961	03/04/97	Cipollina et al.	514	415

## FOREIGN PATENT DOCUMENTS


Examiner Initial		Document No.	Date	Country	Translation	
					YES	NO
PS	22	99/51592	10/14/99	WO	X	
EXAMINER	[Signature]			DATE CONSIDERED	6/19/05	



Sheet 1 of 2

<b>Form PTO-1449 Modified</b>  List of Patent and Publications Cited by Applicant (Use several sheets if necessary)  U.S. Department of Commerce Patent and Trademark Office	Docket No. WYNC-0326/ AM101202(NP)		Application No. 10/659,193		
	Applicant Deborah Ann Evrard, et al.				
	Filing Date September 10, 2003		Group Not Yet Assigned		
	Confirmation No. Not Yet Assigned				
<b>OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)</b>					
	1	Artigas, F., et al., "Pindolol induces a rapid improvement of depressed patients treated with serotonin reuptake inhibitors," <i>Arch Gen Psychiatry</i> , March 1994, 51, 248-251			
	2	Blier, P., et al., "Effectiveness of pindolol with selected antidepressant drugs in the treatment of major depression," <i>J. of Clinical Psychopharmacology</i> , 1995, 15(3), 217-222			
	3	Bundgaard, (Ed.), Design of Prodrugs, <i>Elsevier</i> , 1985			
	4	Bundgaard, H., "Means to enhance penetration; Prodrugs as a means to improve the delivery of peptide drugs," <i>Advanced Drug Deliver Reviews</i> , 1992, 8, 1-38			
	5	Bundgaard, J. of <i>Pharmaceutical Sciences</i> , 1988, 7(285 et seq.)			
	6	Cheetham, S.C., et al., "[ <sup>3</sup> H]paroxetine binding in rat frontal cortex strongly correlates with [ <sup>3</sup> H]5-HT uptake: effect of administration of various antidepressant treatments," <i>Neuropharmacol.</i> , 1993, 32(8), 737-743			
	7	Eliel, E.L., Stereochemistry of Carbon Compounds, <i>McGraw-Hill</i> , NY, 1962			
	8	Hall, M.D., et al., "[ <sup>3</sup> H]8-hydroxy-2-(Di- <i>n</i> -propylamino)tetralin binding to pre- and postsynaptic 5-hydroxytryptamine sites in various regions of the rat brain," <i>J. Neurochem.</i> , 1985, 44, 1685-1696			
	9	Higuchi, et al. (Eds.), Prodrugs as Novel Drug Delivery Systems, <i>American Chemical Society</i> , 1975			
	10	Jacques, et al., Enantiomers, Racemates and Resolutions, <i>Wiley Interscience</i> , NY, 1981			
EXAMINER		DATE CONSIDERED 6/13/05			

\* A copy of these references will not be forwarded to the U.S. Patent and Trademark Office since they are believed to be too voluminous and easily obtainable by the Examiner.



<b>Form PTO-1449 Modified</b>  List of Patent and Publications Cited by Applicant (Use several sheets if necessary)  U.S. Department of Commerce Patent and Trademark Office		Docket No. WYNC-0326/ AM101202(NP)	Application No. 10/659,193
		Applicant Deborah Ann Evrard, et al.	
		Filing Date September 10, 2003	Group Not Yet Assigned
		Confirmation No. Not Yet Assigned	
<b>OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)</b>			
	11	Krogsgaard-Larsen, et al. (Eds.), "Design and Application of Prodrugs," <i>Textbook of Drug Design and Development</i> , 1991, Chap. 5, 113-191	
	12	Lazareno, S., et al., "Pharmacological characterization of acetylcholine-stimulated [ <sup>3</sup> S]-GTPγS binding mediated by human muscarinic m1-m4 receptors: antagonist studies," <i>Br. J. Pharmacol.</i> , 1993, 109, 1120-1127	
	13	Perez, V., et al., "Randomised, double-blind, placebo-controlled trial of pindolol in combination with fluoxetine antidepressant treatment," <i>The Lancet</i> , May 31, 1997, 349, 1594-1597	
*	14	Remington's Pharmaceutical Sciences, 17 <sup>th</sup> Ed., Gennaro, A.R. (Ed.), <i>Mack Publishing Company, Easton, PA, 1985</i>	
	15	Tome, M.B., et al., "Serotonergic autoreceptor blockade in the reduction of antidepressant latency: personality variables and response to paroxetine and pindolol," <i>J. Affect Disord</i> , 1997, 44, 101-109	
	16	Tome, M.B., et al., "Paroxetine and pindolol: a randomized trial of serotonergic autoreceptor blockade in the reduction of antidepressant latency," <i>Int. Clin. Psychopharmacol</i> , 1997, 12, 81-89	
*	17	Widder, et al. (Eds.), <i>Methods in Enzymology, Academic Press, 1985, Vol. 4</i>	
	18	Wilens, S.H., "Tables of Resolving Agents and Optical Resolutions," <i>Univ. of Notre Dame Press, Notre Dame, IN, E.L. Eliel (Ed.), 1972, page 268-298</i>	
	19	Wilens, S.H., et al., "Strategies in optical resolutions," <i>Tetrahedron</i> , 1977, 33, 2725-2736	
<b>EXAMINER</b>		<b>DATE CONSIDERED</b>	

\* A copy of these references will not be forwarded to the U.S. Patent and Trademark Office since they are believed to be too voluminous and easily obtainable by the Examiner.